BioCentury
ARTICLE | Financial News

Autolus follows up CAR T data with $101M raise

April 11, 2019 2:07 PM UTC

Days after announcing the first response rates from a Phase I/II trial of CAR T cell therapy AUTO1, Autolus raised $100.8 million in a follow-on offering.

Late Wednesday, Autolus Therapeutics plc (NASDAQ:AUTL) sold 4.2 million ADSs, each representing one ordinary share, at $24. The price represents a 23% discount to Autolus' close of $31.25 on Monday, when it proposed the offering after market hours. Autolus' shares slid 22% over the next two days to close at $24.30 on Wednesday. Autolus gained $1.35 to $25.65 on Thursday...

BCIQ Company Profiles

Autolus Therapeutics plc